Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Influence of immunoglobulin isotype on therapeutic antibody function.

Literature DB >> 26764357

Influence of immunoglobulin isotype on therapeutic antibody function.

Stephen A Beers¹, Martin J Glennie¹, Ann L White¹.

Abstract

Monoclonal antibody (mAb) therapeutics are revolutionizing cancer treatment; however, not all tumors respond, and agent optimization is essential to improve outcome. It has become clear over recent years that isotype choice is vital to therapeutic success with agents that work through different mechanisms, direct tumor targeting, agonistic receptor engagement, or receptor-ligand blockade, having contrasting requirements. Here we summarize how isotype dictates mAb activity and discuss ways in which this information can be used for the development of enhanced therapeutics.

Entities: Disease

Mesh：

Substances：

Year: 2016 PMID： 26764357 PMCID： PMC4797141 DOI： 10.1182/blood-2015-09-625343

Source DB: PubMed Journal: Blood ISSN： 0006-4971 Impact factor: 22.113

75 in total

Review 1. Fcγ receptors: genetic variation, function, and disease.

Authors: Chantal E Hargreaves; Matthew J J Rose-Zerilli; Lee R Machado; Chisako Iriyama; Edward J Hollox; Mark S Cragg; Jonathan C Strefford
Journal: Immunol Rev Date: 2015-11 Impact factor: 12.988

2. Divergent immunoglobulin g subclass activity through selective Fc receptor binding.

Authors: Falk Nimmerjahn; Jeffrey V Ravetch
Journal: Science Date: 2005-12-02 Impact factor: 47.728

3. Antitumor activities of agonistic anti-TNFR antibodies require differential FcγRIIB coengagement in vivo.

Authors: Fubin Li; Jeffrey V Ravetch
Journal: Proc Natl Acad Sci U S A Date: 2013-11-11 Impact factor: 11.205

4. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.

Authors: Guillaume Cartron; Laurent Dacheux; Gilles Salles; Philippe Solal-Celigny; Pierre Bardos; Philippe Colombat; Hervé Watier
Journal: Blood Date: 2002-02-01 Impact factor: 22.113

Review 5. FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs.

Authors: Ann L White; H T Claude Chan; Ruth R French; Stephen A Beers; Mark S Cragg; Peter W M Johnson; Martin J Glennie
Journal: Cancer Immunol Immunother Date: 2013-03-31 Impact factor: 6.968

6. An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells.

Authors: Nicholas S Wilson; Becky Yang; Annie Yang; Stefanie Loeser; Scot Marsters; David Lawrence; Yun Li; Robert Pitti; Klara Totpal; Sharon Yee; Sarajane Ross; Jean-Michel Vernes; Yanmei Lu; Cam Adams; Rienk Offringa; Bob Kelley; Sarah Hymowitz; Dylan Daniel; Gloria Meng; Avi Ashkenazi
Journal: Cancer Cell Date: 2011-01-18 Impact factor: 31.743

7. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.

Authors: Mark J Selby; John J Engelhardt; Michael Quigley; Karla A Henning; Timothy Chen; Mohan Srinivasan; Alan J Korman
Journal: Cancer Immunol Res Date: 2013-04-07 Impact factor: 11.151

8. IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells.

Authors: D Herlyn; H Koprowski
Journal: Proc Natl Acad Sci U S A Date: 1982-08 Impact factor: 11.205

Review 9. Engineering therapeutic antibodies for improved function.

Authors: L G Presta; R L Shields; A K Namenuk; K Hong; Y G Meng
Journal: Biochem Soc Trans Date: 2002-08 Impact factor: 5.407

10. Inhibitory FcγRIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity.

Authors: Andrew T Vaughan; Chisako Iriyama; Stephen A Beers; Claude H T Chan; Sean H Lim; Emily L Williams; Vallari Shah; Ali Roghanian; Bjorn Frendéus; Martin J Glennie; Mark S Cragg
Journal: Blood Date: 2013-11-13 Impact factor: 22.113

51 in total

Review 1. Integrative Pharmacology: Advancing Development of Effective Immunotherapies.

Authors: Mohammad Tabrizi; Daping Zhang; Vaishnavi Ganti; Glareh Azadi
Journal: AAPS J Date: 2018-04-27 Impact factor: 4.009

Review 2. Considerations for the Design of Antibody-Based Therapeutics.

Authors: Dennis R Goulet; William M Atkins
Journal: J Pharm Sci Date: 2019-06-04 Impact factor: 3.534

3. Evidence of disulfide bond scrambling during production of an antibody-drug conjugate.

Authors: Lily Pei-Yao Liu-Shin; Adam Fung; Arun Malhotra; Gayathri Ratnaswamy
Journal: MAbs Date: 2018-10-19 Impact factor: 5.857

Review 4. Multivalent Antibody-Recruiting Macromolecules: Linking Increased Binding Affinity with Enhanced Innate Immune Killing.

Authors: Annemiek Uvyn; Bruno G De Geest
Journal: Chembiochem Date: 2020-07-10 Impact factor: 3.164